Nodality, Inc., an innovative biotechnology company advancing discovery,
development and use of transformative therapies by revealing functional
systems biology, announced today promising data utilizing the company's
proprietary Single Cell Network Profiling (SCNP) technology
in metastatic melanoma.
The study results were featured in a late-breaking poster presentation
titled, Systems biology analysis of immune signaling in peripheral
blood mononuclear cells (PBMC) of melanoma patients receiving
ipilimumab; basis for clinical response biomarker identification (Abstract
p257), at the SITC 2013 Annual Meeting. The presented data were
generated as part of a collaboration with the G. Pascale National Tumor
Foundation, Naples, Italy, with a team led by Dr. Paolo Ascierto. In
addition, Alessandra Cesano, M.D., Ph.D., Chief Medical Officer of
Nodality, delivered an oral presentation titled, A Single Cell
Network Profiling (SCNP) view of the immune system, focusing on the
use of SCNP to interrogate the basis of cancer immune tolerance and the
activity profiling of immunotherapeutics.
“This innovative, clinically standardized technology provides the unique
opportunity to profile the dynamic processes that associate with disease
and its progression,” said Dr. Franco Marincola, SITC President and
Chief Research Officer of the Sidra Medical and Research Centre, Doha,
Qatar. “Functional immune profiling has the potential to inform on drug
mechanism of action, critical to rational combination strategies and
patient stratification. Such a methodology is critical in a time when
cancer immunotherapeutics have demonstrated efficacy and new agents are
entering the phase of clinical testing.”
To generate these results, the researchers applied Nodality's
proprietary SCNP technology, a multiparametric flow cytometry-based
assay that reveals functional biology by measuring the activity of
protein pathway signaling at the single cell level.
About Single Cell Network Profiling
Single Cell Network Profiling (SCNP)
is a proprietary technology licensed from Stanford University to
characterize cell signaling networks in immunology and cancer. SCNP, by
measuring functional signaling network behavior at the level of the
single cell, has several advantages over other currently used molecular
technologies. These include unprecedented insight into the presence and
clinical meaning of functional cellular heterogeneity in otherwise
molecularly and phenotypically homogeneous tissues, including the
identification of rare cell subsets such as drug-resistant and stem
cells. As such, the technology has widespread application in preclinical
drug development, clinical drug development and diagnostic development.
About Nodality
Nodality is a next-generation life sciences company that is advancing
drug discovery, therapeutic development, and precision medicine by
delivering critical and clinically actionable information to reveal
biology, define disease, and improve health. Nodality's unique,
innovative, and proprietary platform, Single Cell Network Profiling or
SCNP, enables the promise of precision medicine by unlocking the
potential of therapeutics and by matching therapies with the right
patients. SCNP enables functional characterization of disease-associated
signaling at the individual patient level, enabling optimization of
treatment tailored to target the biology driving the disease. Nodality
is applying SCNP to develop molecular diagnostics to improve clinical
decision-making in cancer and autoimmune diseases, with the lead
products targeting treatment management in hematological malignancies.
Nodality is also collaborating with Pharma partners on patient
stratification & companion diagnostics development, drug & disease
profiling, determination of mechanism of action, mechanism-based
competitive differentiation, whole blood PD assays, and biomarker
discovery & development. These applications can result in increased
probability of success, reduced timeline for clinical development, and
differentiation from competitors in the marketplace. Nodality
established multi-year pharma strategic collaborations with UCB Pharma
S.A. (Euronext Brussels: UCB) and Pfizer (NYSE: PFE) in 2012 utilizing
its SCNP technology to assist the development of several compounds
focusing initially on immunology disorders. For more information on
Nodality, please visit www.nodalityinc.com.
Copyright Business Wire 2013